Biodexa Pharmaceuticals (BDRX) EBIT (2013 - 2025)

Biodexa Pharmaceuticals has disclosed EBIT across 13 years of filings, most recently posting -$5.4 million for Q2 2025.

• In Q2 2025, EBIT changed N/A year-over-year to -$5.4 million; the TTM figure through Jun 2025 stood at -$26.0 million (changed N/A YoY), while the FY2025 annual figure was -$11.4 million, up 3.06% from the prior year.
• EBIT came in at -$5.4 million for Q2 2025 at Biodexa Pharmaceuticals, up from -$5.4 million in the prior quarter.
• In the past five years, EBIT ranged from a high of -$4.5 million in Q3 2021 to a low of -$10.5 million in Q4 2022.
• Average EBIT over 5 years is -$6.9 million, with a median of -$5.4 million recorded in 2024.
• Year-over-year, EBIT soared 80.55% in 2021 and dropped 11.06% in 2022.
• Over 5 years, EBIT stood at -$9.4 million in 2021, then retreated by 11.06% to -$10.5 million in 2022, then increased by 5.06% to -$9.9 million in 2023, then surged by 45.51% to -$5.4 million in 2024, then advanced by 1.16% to -$5.4 million in 2025.
• Per Business Quant data, the three most recent EBIT figures were -$5.4 million in Q2 2025, -$5.4 million in Q4 2024, and -$9.9 million in Q4 2023.